Background: Many epidemiological, clinical, and experimental reports have demonstrated an association between serum uric acid concentration and a variety of cardiovascular and renal diseases, particularly in hypertension. At present, there seems to be no resolution to the question whether this relationship is causal or coincidental. Summary: This discussion examines a number of biological, pathophysiological, fundamental, and clinical relationships between serum uric acid concentration and several of these disorders. To this end, discussion and review provide some specific insight conclusions and recommendations related to their clinical relevance. Key Messages: We suggest that, in most instances (especially in patients with essential hypertension), the increase in serum uric acid concentration is coincidental, serving as a useful biomarker that relates the magnitude of circulating plasma uric acid concentration with the extent of impaired cardiovascular and renal function. Moreover, the value of certain pharmaceutical agents affecting the serum uric acid level should be considered carefully by taking into consideration the associated pathophysiological derangements.

Keywords:
Serum uric acid concentration, Biomarker, Intrarenal hemodynamics, Hypertension, Cardiovascular diseases, Renal diseases
1.
Stanton JR, Freis ED: Serum uric acid concentration in essential hypertension. Proc Soc Exp Biol Med 1947;66:193-194.
2.
Mahomed FA: On chronic Bright's disease and its essential symptoms. Lancet 1879;1:399-401.
3.
Davis N: The cardiovascular and renal relations and manifestations of gout. JAMA 1897;29:261-262.
4.
Gertler MM, Garn SM, Kevine SA: Serum uric acid in relation to age and physique in health and in coronary heart disease. Ann Intern Med 1951;34:1421-1431.
5.
Messerli FH, Frohlich ED, Dreslinski GR, Suarez DH, Aristimuno GG: Serum uric acid in essential hypertension: an indicator of renal vascular involvement. Ann Intern Med 1980;93:817-821.
6.
Kahn HA, Medalie JH, Nefeld JH Riss E, Goldbourt U: The incidence of hypertension and associated factors: the Israel Ischemic Heart Study. Am Heart J 1972;84:171-182.
7.
Chen JH, Chuang SY, Chen HJ, Yeh WT, Pan WH: Serum uric acid level as an independent risk factor for all-cause, cardiovascular, and ischemic stroke mortality. Arthritis Rheum 2009;61:225-232.
8.
Obermayr RP, Temml C, Gutjahr G, Knechtelsdorfer M, Oberbauer R, Klauser-Braun R: Elevated uric acid increases the risk for kidney disease. J Am Soc Nephrol 2008;19:2407-2413.
9.
Sesoko S, Pegram BL, Willis GW, Frohlich ED: DOCA-salt induced malignant hypertension in spontaneously hypertensive rats. J Hypertens 1984;2:49-54.
10.
Sanchez-Lozada LG, Tapia E, Santamaría J, Avila-Casado C, Soto V, Nepomuceno T, Rodríguez-Iturbe B, Johnson RJ, Herrera-Acosta J: Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats. Kidney Int 2005;67:237-247.
11.
Feig DI, Kung DH, Johnson RJ: Uric acid and cardiovascular risk. N Engl J Med 2008;359:1811-1821.
12.
Frohlich ED: Uric acid: a risk factor for coronary heart disease. JAMA 1993;270:378-379.
13.
Zoccali C, Mallamaci F: Uric acid, hypertension, and cardiovascular and renal complications. Curr Hypertens Rep 2013;15:531-537.
14.
Niskanen LK, Laaksonen DE, Nyyssönen K, Alfthan G, Lakka HM, Lakka TA, Salonen JT: Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle aged man: a prospective cohort study. Arch Intern Med 2004;164:1546-1551.
15.
Wu X, Muzny DM, Lee CC, Caskey CT: Two independent mutational events in the loss of urate oxidase during hominoid evolution. J Mol Evol 1992;34:78-84.
16.
Watanabe S, Kang DH, Feng L, Nakagawa T, Kanellis J, Lan H, Mazzali M, Johnson RJ: Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. Hypertension 2002;40:355-360.
17.
Richette P, Bardin T: Gout. Lancet 2010;375:318-328.
18.
Zhou X, Matavelli L, Frohlich ED: Uric acid: its relationship to renal hemodynamics and the renal renin-angiotensin system. Curr Hypert Rep 2006;8:120-124.
19.
Bellomo G: Uric acid and chronic kidney disease: a time to act? World J Nephrol 2013;2:17-25.
20.
Pascual E, Perdiguero M: Gout, diuretics and the kidney. Ann Rheum Dis 2006;65:981-982.
21.
Alvarez-Lario B, Maccaron-Vicente J: Is there anything good in uric acid? Q J Med 2011;104:1015-1024.
22.
Glantzuonis G, Tsimoyiannis E, Kappas A, Galaris D: Uric acid and oxidative stress. Curr Pharm Des 2005;11:4145-4151.
23.
Sofaer JA, Emery AEH: Genes for super-intelligence. J Med Genet 1981;18:410-413.
24.
Toncev G, Milicic B, Toncev S, Samardzic G: Serum uric acid levels in multiple sclerosis patients correlate with activity of disease and blood-brain barrier dysfunction. Eur J Neurol 2002;9:221-226.
25.
Chen H, Mosley TH, Alonso A, Huang X: Plasma urate and Parkinson's disease in the atherosclerosis risk in communities (ARIS) study. Am J Epidemiol 2010;172:666-670.
26.
Irizarry MC, Raman R, Schwarzschild MA, Becerra LM, Thomas RG, Peterson RC, Ascherio A, Aisen PS: Plasma urate and progression of mild cognitive impairment. Neurodegener Dis 2009;6:23-28.
27.
Johnson RJ, Rideout BA: Uric acid and diet - insights into the epidemic of cardiovascular disease. N Engl J Med 2004;350:1071-1073.
28.
Francischetti A, Ono H, Frohlich ED: Renoprotective effects of felodipine and/or enalapril in spontaneously hypertensive rats with and without L-NAME. Hypertension 1998;31:795-801.
29.
Nakamura Y, Ono H, Zhou X, Frohlich ED: Angiotensin type 1 receptor antagonism and ACE inhibition produce produce similar renoprotection in N-nitro-L-arginine methylester/spontaneously hypertensive rats. Hypertension 2001;37:1262-1267.
30.
Zhou X, Matavelli LC, Ono H, Frohlich ED: Superiority of combination of thazide with angiotensin-converting enzyme inhibitor or AT1-receptor blocker over thiazide alone on renoprotection in L-NAME/SHR. Am J Physiol Renal Physiol 2005;289:F871-F879.
31.
Uchino K, Nishikimi T, Frohlich ED: α1-Adrenergic receptor blockade reduces afferent and efferent glomerular arteriolar resistances in SHR. Am J Physiol 1991;261:R576-R580.
32.
Ono H, Ono Y, Frohlich ED: Nitric oxide synthase inhibition in spontaneously hypertensive rats. Systemic, renal, and glomerular hemodynamics. Hypertension 1995;26:249-255.
33.
Komatsu K, Frohlich ED, Ono H, Ono Y, Numabe A, Willis GW: Glomerular dynamics and morphology of aged spontaneously hypertensive rats: effects of angiotensin-converting enzyme inhibition. Hypertension 1995;25:207-213.
34.
Zhou X, Ono H, Ono Y, Frohlich ED: Aldosterone antagonism ameliorates proteinuria and nephrosclerosis independent of glomerular dynamics in L-NAME/SHR model. Am J Nephrol 2004;24:242-249.
35.
Wu X, Wakamiya M, Vaishnav S, Geske R, Montgomery C Jr, Jones P, Bradley A, Caskey CT: Hyperuricemia and urate nephropathy in urate oxidase-deficient mice. Proc Natl Acad Sci USA 1994;91:742-746.
36.
Mazzali M, Huges J, Kim YG, Jefferson JA, Kang DH, Gordon KL, Lan HY, Kivlighn S, Johnson RJ: Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 2001;38:1101-1106.
37.
Sanchez-Lozada LG, Tapia E, Santamaria J, Avila-Casado C, Soto V, Nepomuceno T, Rodriguez-Iturbe B, Johnson RJ, Herrera-Acosta J: Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats. Kidney Int 2005;67:237-247.
38.
Mazzali M, Kanellis J, Han L, Feng L, Xia YY, Chen Q, Kang DH, Gordon LL, Watanabe S, Nakagawa T, Lan HY, Johnson RJ: Hyperuricemia induces primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol 2002;282:F991-F997.
39.
Nakagawa T, Mazzali M, Kang DH, Kanellis J, Watanabe S, Sanchez-Lozada LG, Rodriguez- Iturbe B, Herrera-Acosta J, Johnson RJ: Hyperuricemia causes glomerular hypertrophy in the rat. Am J Nephrol 2003;23:2-7.
40.
Kang DH, Nakagawa T, Feng L, Johnson RJ: Nitric oxide modulates vascular disease in the remnant kidney model. Am J Pathol 2002;161:239-248.
41.
Khosla UM, Zharikov S, Finch J: Hyperuricemia induces endothelial dysfunction. Kidney Int 2005;67:1739-1742.
42.
Kanellis J, Watanabe S, Li JH, Kang DH, Li P, Nakagawa T, Wamsley A, Sheikh-Hamad D, Lan HY, Feng L, Johnson RJ: Uric acid simulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension 2003;41:1287-1293.
43.
Feig DI, Mazzali M, Kang DH, Nakagawa T, Price K, Kannelis J, Johnson RJ: Serum uric acid: a risk factor and a target for treatment? J Am Soc Nephrol 2006;17:S69-S73.
44.
Durante P, Chavez M, Perez M, Romero F, Rivera F: Effects of uric acid in spontaneously hypertensive rats. Life Sci 2010;86:957-964.
45.
Johnson RJ, Sanchez-Lozada LG, Mazzali M, Feig DI, Kanbay M, Sautin YY: What are the key arguments against uric acid as a true risk factor for hypertension? Hypertension 2013;61:948-951.
46.
Ferris TF, Gorden P: Effect of angiotensin and norepinephrine upon urate clearance in man. Am J Med 1968;44:359-365.
47.
Kobrin I, Frohlich ED, Ventura O, Messerli FH: Renal involvement follows cardiac enlargement in essential hypertension. Arch Intern Med 1986;146:272-276.
48.
Nunez BD, Frohlich ED, Garavaglia GE, Schmieder RE, Nunez MM: Serum uric acid in renovascular hypertension. Am J Med Sci 1987;294:419-422.
49.
Culleton BF, Larson MG, Kannel WB, Levy D: Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med 1999;131:7-13.
50.
Krishnan E, Kwoh CK, Schumacher HR, Kuller L: Hyperuricemia and incidence of hypertension among men without metabolic syndrome. Hypertension 2007;49:298-303.
51.
Ben-Dov IZ, Kark JD: Serum uric acid is a GFR-independent long-term predictor of acute and chronic renal insufficiency: The Jerusalem Lipid Research cohort study. Nephrol Dial Transplant 2011;26:2558-2566.
52.
Oh CM, Park SK, Ryoo JH: Serum uric acid level is associated with the development of microlabuminuria in Korean men. Eur J Clin Invest 2014;44:4-12.
53.
Feig DI: Serum uric acid and the risk of hypertension and chronic kidney disease. Curr Opin Rheumatol 2014;26:176-185.
54.
Feig DI, Soletsky B, Johnson RJ: Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA 2008;300:924-932.
55.
Soletsky B, Feig DI: Uric acid reduction rectifies prehypertension in obese adolescents. Hypertension 2012;60:1148-1156.
56.
Chaudhary K, Malhotra K, Sowers J, Aroor A: Uric acid - key ingredient in the recipe for cardiorenal metabolic syndrome. Cardiorenal Med 2013;3:208-220.
57.
Gigante A, Liberatori M, Gasperini ML, Sardo L, Di Mario F, Dorelli B, Barbano B, Rosato E, Rosi Fanelli F, Amoroso A: Prevalence and clinical features of patients with cardiorenal syndrome admitted to an internal medicine ward. Cardiorenal Med 2014;4:88-94.
58.
Jia G, Aroor AR, Sowers JR: Arterial stiffness: a nexus between cardiac and renal disease. Cardiorenal Med 2014;4:60-71.
59.
Lee CT, Huang CC, Hsu CY, Chiou TT, Ng HY, Wu CH, Kuo WH, Lee YT: Calcification of aortic arch predicts cardiovascular and all-cause mortality in chronic hemodialysis patients. Cardiorenal Med 2014;4:34-42.
60.
Kushiyama A, Tanaka K, Hara S, Kawazu S: Linking uric acid metabolism to diabetic complications. World J Diabetes 2014;5:787-795.
61.
Richette P, Perez-Ruiz F, Doherty M, Jansen TL, Nuki G, Pascual E, Punzi L, So AK, Bardin T: Improving cardiovascular and renal outcomes in gout: what should we target? Nat Rev Rheumatol 2014;10:654-661.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.